Pulmonary alveolar proteinosis

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Critical Care Medicine (journal), PAP, Pulmonary alveolar proteinosis, AJRCCM, Abstract, American Journal, Conference, APAP, Diagnosis

The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine (AJRCCM) on May 1, 2024.

Key Points: 
  • The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine (AJRCCM) on May 1, 2024.
  • For more details about the ATS International Conference please visit https://conference.thoracic.org/index.php .
  • Pulmonary Alveolar Proteinosis (PAP): Pathophysiology, Diagnosis, and Management
    Bruce Trapnell, M.D., M.S.
  • will provide an overview of PAP, including the burden of this rare lung disease, the hallmark signs and symptoms of autoimmune PAP (aPAP), the most common form of PAP, and the path to diagnosing aPAP.

Partner Therapeutics' Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Retrieved on: 
Wednesday, April 3, 2024
Monocyte, GM, Serum, Disease, Partnership, Patient, GM-CSF, DNA, PTX, Doctor of Philosophy, Respiratory failure, Pleasure, Trade name, Granulocyte-macrophage colony-stimulating factor, Pulmonary fibrosis, APAP, Therapy, Niigata University, Pulmonary alveolar proteinosis, Division, Partner, PMDA, PAGE, CEA, WLL, Hospital

LEXINGTON, Mass., April 3, 2024 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) announced that its partner Nobelpharma received approval from the Japanese Pharmaceuticals and Medical Device Agency (PMDA) for the inhaled use of Leukine (sargramostim), branded in Japan as Sargmalin, to treat aPAP. PTx licensed rights for certain indications in Japan to Nobelpharma in 2022. Leukine is a glycosylated recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in yeast. Leukine is not approved outside Japan for aPAP or as an inhalation therapy. Partner Therapeutics will manufacture Sargmalin for Nobelpharma at its manufacturing facility in Lynnwood, WA.

Key Points: 
  • Leukine is not approved outside Japan for aPAP or as an inhalation therapy.
  • Partner Therapeutics will manufacture Sargmalin for Nobelpharma at its manufacturing facility in Lynnwood, WA.
  • Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients.
  • Autoimmune pulmonary alveolar proteinosis.

aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference

Retrieved on: 
Monday, May 22, 2023
Sarcoidosis, Myelocyte, Inflammation, Macrophage, Small RNA, Neuropilin, ATyr Pharma, ATS, DC, Immunoassay, ILD, IL-6, Tumor necrosis factor, Research, FC, Macrophage inflammatory protein, American Thoracic Society, Biomarker, Monocyte, Vital capacity, International Conference on Creationism, Patient, SAN, Flow cytometry, Pulmonary alveolar proteinosis, Phenotype, Safety, Convention center, Conference, MCP-1, Disease, Medical imaging, Pharmaceutical industry, Fibrosis

SAN DIEGO, May 22, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2023 International Conference, which is scheduled to take place May 19 – 24 in Washington, DC.

Key Points: 
  • Exposure-efficacy data from Phase 1b/2a study of efzofitimod support efficacy across multiple clinically relevant endpoints in pulmonary sarcoidosis patients.
  • “We present new data showing that by binding to neuropilin-2, efzofitimod modulates immune responses through myeloid cells.
  • By targeting multiple drivers of inflammation, efzofitimod provides a differentiated approach to resolving chronic inflammation.
  • aTyr is currently conducting EFZO-FIT™, a global pivotal Phase 3 study of efzofitimod in pulmonary sarcoidosis.

Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022

Retrieved on: 
Tuesday, September 6, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, People, WLL, Fatigue, Fever, Article, Sex, Safety, Lipid, PAP, Degenerative disease, Chest (journal), Protein, Macrophage, Chronic cough, Exercise, Carbon monoxide, LinkedIn, GM-CSF, Granulocyte-macrophage colony-stimulating factor, APAP, ERJ, Antibody, Inc., Patient, Health status of Asian Americans, European Respiratory Journal, Respiratory tract infection, Pulmonary alveolar proteinosis, Twitter, Yolk sac, Congress, Clinical trial, Pulmonology, Common, Pharmaceutical industry, Vaccine, Medical imaging, Publication, Savara, IMPALA

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2022 that took place September 4-6th in Barcelona, Spain.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2022 that took place September 4-6th in Barcelona, Spain.
  • Additionally, patients reported improved health status, as measured by St. Georges Respiratory Questionnaire-Total and -Activity, when compared with placebo-treated patients .
  • Abstract #1154: Safety and Tolerability of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) presented by F. Bonella, M.D., Ph.D.
  • Additionally, the posters are scheduled to be published in a supplement of the European Respiratory Journal (ERJ) by the end of November 2022.

Savara Announces Resignation of Chief Medical Officer

Retrieved on: 
Friday, August 26, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, CEO, Degenerative disease, Chair, LinkedIn, GM-CSF, APAP, Granulocyte-macrophage colony-stimulating factor, Inc., Leadership, Pulmonary alveolar proteinosis, Twitter, Molgramostim, Pulmonology, Pharmaceutical industry

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief Medical Officer, effective September 9, 2022.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief Medical Officer, effective September 9, 2022.
  • We appreciate Dr. Chowdhurys contributions during his tenure with the company, said Matt Pauls, Chair and CEO, Savara.
  • His leadership helped progress our molgramostim nebulizer solution (molgramostim) development program through some important milestones and we wish him well in the future.
  • Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.

Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Retrieved on: 
Thursday, August 25, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, People, Medicines and Healthcare products Regulatory Agency, COVID-19, Fatigue, Fever, CEO, Sex, Lipid, Program, PAP, Regulation of tobacco by the U.S. Food and Drug Administration, Degenerative disease, Protein, Macrophage, Chronic cough, Exercise, Chair, Food, LinkedIn, Diagnosis, SEC, GM-CSF, Review, APAP, Method, Granulocyte-macrophage colony-stimulating factor, Antibody, Inc., FDA, EAMS, Therapy, MHRA, Pulmonary alveolar proteinosis, Form, Twitter, Molgramostim, Yolk sac, Pulmonology, Private Securities Litigation Reform Act, PIM, Forward-looking statement, Patient, Pharmaceutical industry, Savara

Medicines with a positive scientific opinion could be made available to UK patients 12-18 months before formal marketing authorization is granted.

Key Points: 
  • Medicines with a positive scientific opinion could be made available to UK patients 12-18 months before formal marketing authorization is granted.
  • On June 15, 2022, molgramostim was awarded Innovation Passport designation by MHRA.
  • Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disease that belongs to a family of distinct rare lung diseases collectively known as pulmonary alveolar proteinosis (PAP).
  • Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022

Retrieved on: 
Monday, July 11, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, People, Fever, Lipid, LinkedIn, 2021 Essex County Council election, Degenerative disease, Yolk sac, Fatigue, GM-CSF, Sex, Chronic cough, Pulmonology, European Respiratory Journal, Granulocyte-macrophage colony-stimulating factor, Congress, ERJ, Inc., Exercise, APAP, Pulmonary alveolar proteinosis, Patient, Twitter, Savara, Chest (journal), Macrophage, Protein, PAP, Antibody, Vaccine

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the ERS International Congress 2022 to be held in-person and virtually, September 4-6, 2022 in Barcelona, Spain.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the ERS International Congress 2022 to be held in-person and virtually, September 4-6, 2022 in Barcelona, Spain.
  • The full content of these abstracts will be available in the Congress online program and will be published in a supplement of the European Respiratory Journal (ERJ) by the end of November 2022.
  • For more details about the ERS International Congress please visit https://www.ersnet.org/congress-and-events/congress/ .
  • Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.

HME Strategic Audience Acquisition Plan Delivers Engagement by Medical Specialists

Retrieved on: 
Thursday, February 3, 2022
Technology, Software, Practice Management, Internet, Continuing, Training, Health, General Health, Education, Manna, Faculty, Patient, ACCME, Infection, Continuing medical education, Toxicity, CME, Accreditation Council for Continuing Medical Education, Accreditation, HME, Pulmonary alveolar proteinosis, Sickle cell disease, Marketing, Â, Accreditation Council, Partnership, Program, Pediatrics, Neurology, Acquisition, Education, Investment, Medical education, Medicine, Pharmaceutical industry

Haymarket Medical Education (HME), announced today the continuation of its audience acquisition initiative based on its success in increasing new registrations and engagement among specialists as well as increased participation in CME/CE activities across the myCME site.

Key Points: 
  • Haymarket Medical Education (HME), announced today the continuation of its audience acquisition initiative based on its success in increasing new registrations and engagement among specialists as well as increased participation in CME/CE activities across the myCME site.
  • One of the many major investments myCME continues to make to offer a broad range of education for its growing national and international audience of learners, the acquisition plan was designed to attract medical specialists through the high caliber of its educational content and faculty.
  • With our commitment to provide learners, partners, and grantors with the tools and information they need to treat the whole patient and improve the care of all patients, the HME audience acquisition plan has been a win-win initiative, said Mary Manna-Anderson, Group President, Medical Education.
  • In 2022, the HME audience acquisition plan is expected to launch dozens of new activities.

Ethris Raises $26.3 Million Series B to Advance Pipeline of mRNA-based Therapeutics for Respiratory Diseases

Retrieved on: 
Tuesday, February 1, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Health status of White Americans, CEO, III, Patient, Degenerative disease, Pulmonary alveolar proteinosis, Deloitte Technology Fast 500, Zebrafish, RNA transfection, Founder, Biotechnology, PCD, EY, Mark (given name), Respiratory system, Program, Series, Autoimmune disease, Gene, Survival, Severe acute respiratory syndrome coronavirus 2, PAP, Therapy, Primary ciliary dyskinesia, Protein, RNA, LNP, Vaccine, Laureus World Sports Awards

Ethris GmbH , a leading biotechnology company pioneering transformative messenger RNA (mRNA) therapeutics, announced today that it has raised $26.3 Million (23.3 Million) in a Series B financing round led by Laureus Capital.

Key Points: 
  • Ethris GmbH , a leading biotechnology company pioneering transformative messenger RNA (mRNA) therapeutics, announced today that it has raised $26.3 Million (23.3 Million) in a Series B financing round led by Laureus Capital.
  • Raising this Series B financing represents an important milestone for Ethris and validates the potential of our proprietary mRNA and LNP delivery platforms and the expert team we have built, said Dr. Carsten Rudolph, CEO of Ethris.
  • I welcome Christian to our executive team and am looking forward to his expertise as we enter the next phase of our growth.
  • We are rapidly advancing our pipeline of immuno-modulation and mRNA-based protein replacement therapies with the ultimate goal of improving patients lives.

Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021

Retrieved on: 
Monday, November 22, 2021
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, 2021 Essex County Council election, Government, British Thoracic Society, CEO, C-reactive protein, Death, MD, CRP, Pulmonary alveolar proteinosis, COVID-19, Nasdaq, Chief executive officer, Incidence, Nursing, United Kingdom, Randomness, Pharmaceutical industry, ISARIC Coronavirus Clinical Characterisation Consortium (4C) Mortality Score, Humanigen, Inc., ISARIC CORONAVIRUS CLINICAL CHARACTERISATION CONSORTIUM (4C) MORTALITY SCORE, HUMANIGEN, INC.

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced three abstracts pertaining to the potential use of lenzilumab in hospitalized COVID-19 patients will be presented at the British Thoracic Society Winter 2021 Meeting taking place Nov. 24-26, 2021.

Key Points: 
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced three abstracts pertaining to the potential use of lenzilumab in hospitalized COVID-19 patients will be presented at the British Thoracic Society Winter 2021 Meeting taking place Nov. 24-26, 2021.
  • The society counts more than 4,000 members comprised of doctors, nurses, respiratory physiotherapists, scientists, and other professionals with a respiratory interest.
  • The study also demonstrated significant improvement in SWOV for the predefined subgroup of subjects who received both corticosteroids and remdesivir (HR: 1.92; nominal p=0.0067).
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.